Publication | Closed Access

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

FibrosisAntifibrotic TherapyInflammatory Lung DiseaseAdvanced Lung DiseaseLung InflammationIdiopathic Pulmonary FibrosisPathologyPulmonary Alveolar ProteinosisPulmonary FibrosisPlacebo-controlled TrialPulmonary MedicinePhase 2Medicine